Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05730660
Other study ID # 0912/01072022
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date January 31, 2023

Study information

Verified date February 2023
Source Azienda di Servizi alla Persona di Pavia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether a 3-month period of quercetin supplementation (500 mg of Quercetin Phytosome®) is useful in the treatment of chronic fatigue, as assessed by the Fatigue Impact Scale (FIS-40). Secondary end points are sleep assessment through Pittsburgh Sleep Quality Index (PSQI) and muscle performance assessment through the Short Physical Performance Battery (SPPB) and body composition assessment using DXA.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date January 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age = 18 years old - confirmed diagnosis of chronic fatigue syndrome according to the 1994 CDC / Fukuda definition Exclusion Criteria: - patients with any active medical condition that explained chronic fatigue (untreated hypothyroidism, sleep apnea, narcolepsy, drug side effects and iron deficiency anemia), previous diagnosis not unequivocally resolved (chronic hepatitis, malignant tumors), past neuropsychiatric disorders o current (severe depressive disorder with psychotic or melancholy features, bipolar disorder, schizophrenia, delusional disorder, dementia, anorexia nervosa, bulimia nervosa) and participation in another clinical trial of the same or different nature within 30 days prior to inclusion in the study; failure to provide signed informed consent; consumption of certain drugs / supplements that could affect outcome measures in the past 90 days or whose discontinuation could be a significant problem, anticoagulant treatment, pregnancy or breastfeeding, smoking, alcohol or substance abuse, obesity (BMI> 30 kg / m2).

Study Design


Intervention

Dietary Supplement:
Quercetin group
2 capsules a day of Quercetin Fitosoma® of 250 mg each
Placebo group
2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.

Locations

Country Name City State
Italy l'Istituto di Riabilitazione e cura "Santa Margherita" di Pavia, Azienda di Servizi alla Persona (ASP). Pavia

Sponsors (1)

Lead Sponsor Collaborator
Azienda di Servizi alla Persona di Pavia

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary chronic fatigue syndrome The primary outcome is the change in self-reported fatigue scores assessed using the Fatigue Impact Scale (FIS-40) At baseline and after 3 months
Secondary Sleep quality Sleep disturbances are assessed using the 19-item self-administered Pittsburgh Sleep Quality Index (PSQI) questionnaire. Scores are obtained on each of the seven sleep quality domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping pills, and daytime dysfunction. Each component is rated from 0 to 3 (0 = no sleep problems and 3 = severe sleep problems). The overall PSQI score ranges from 0 to 21 points, with scores =5 indicating worse sleep quality At baseline and after 3 months
Secondary Physical performance Physical performance is assessed using the Short Physical Performance Battery test At baseline and after 3 months
Secondary Body composition Body composition is assessed using the dual X-Ray absorptiometry (DXA) At baseline and after 3 months
Secondary Life quality Quality of life is assessed using the Short-Form 12-Item Health Survey (SF-12), a short and generic measure of health status that reproduces the 2 summary scores of the SF-36, the summary of the physical component score and the summary score of the mental component, addressing eight health domains (physical functioning, physical role, body pain, general health, vitality, social functioning, emotional role and mental health) At baseline and after 3 months
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Recruiting NCT06079853 - Nurse Suicide: Physiologic Sleep Health Promotion Trial N/A
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT04513743 - Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ N/A
Completed NCT03251274 - Bath Machine on Sleep Quality in Nursing Home N/A
Completed NCT04102345 - Lavender vs Zolpidem Sleep Quality During Diagnostic PSG Early Phase 1
Completed NCT03725943 - Comparison of Dreem to Clinical PSG for Sleep Monitoring in Healthy Adults N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT04562181 - Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index N/A
Completed NCT05102565 - A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers N/A
Completed NCT05576844 - Ai Youmian (Love Better Sleep) for People Living With HIV N/A
Completed NCT04688099 - Synovial Fluid Sleep Study
Recruiting NCT04171245 - Prescribing Laughter for Sleep and Wellbeing in UAE University Students N/A
Completed NCT03758768 - The Effects of a Blue Monochromatic Light Intervention on Evening-type Individuals' Sleep and Circadian Rhythms N/A
Completed NCT03163498 - Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients
Completed NCT04093271 - Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep Phase 1
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04120363 - Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations Phase 4